Notice: This company has been marked as potentially delisted and may not be actively trading. Range Cancer Therapeutics ETF Rating Add Compare Share Share Ratings Stock AnalysisDividendHeadlinesHoldingsRatingsShort InterestTrends Range Cancer Therapeutics ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CNCR Aggregate RatingModerate Buy 2.82Holdings in CNCR have an aggregate rating of Moderate Buy based on 429 analyst ratings issued in the past year covering 50 companies (73.5% of the portfolio).CNCR Aggregate Price Target$13.42High Prediction$13.42Average Prediction$13.42Low Prediction$13.42Holdings in CNCR have an aggregate price target of $13.42 and a range of $13.42 to $13.42 covering 50 companies (73.5% of the portfolio).CNCR Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy23 Buy rating(s)Moderate Buy20 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce2 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Range Cancer Therapeutics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 CNCR Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.13%GLUEMonte Rosa Therapeutics$8.40+0.5%2.9694 of 5 stars3.00$16.00 90.5%31.97%IBRXImmunityBio$4.91+0.6%0.7361 of 5 stars3.00$4.75 -3.3%2Positive News1.83%ZYMEZymeworks$14.07-3.3%2.4008 of 5 stars2.83$19.00 35.0%61.82%RVMDRevolution Medicines$57.21+0.2%2.7869 of 5 stars3.08$61.00 6.6%121.80%MRSNMersana Therapeutics$2.16-2.7%4.3672 of 5 stars2.88$6.00 177.8%8Analyst Revision1.80%EXELExelixis$34.52-0.4%4.7895 of 5 stars2.65$31.44 -8.9%20Insider Trade1.74%ACLXArcellx$86.18-1.2%2.9324 of 5 stars3.07$103.08 19.6%14Short Interest ↓1.65%BMYBristol-Myers Squibb$57.97+0.2%4.7873 of 5 stars2.20$54.07 -6.7%20Analyst Revision1.65%DNAGinkgo Bioworks$6.44+1.3%1.1366 of 5 stars1.60$4.58 -29.0%5Short Interest ↓1.63%GNLXGenelux$2.40-3.6%1.3414 of 5 stars3.20$18.25 660.4%5Gap Up1.57%ELVNEnliven Therapeutics$25.15-1.1%2.3739 of 5 stars3.25$37.00 47.1%41.57%MGNXMacroGenics$3.19-2.7%3.8708 of 5 stars2.36$7.63 139.0%111.57%XNCRXencor$23.69-0.1%3.5491 of 5 stars3.00$35.75 50.9%81.56%BPMCBlueprint Medicines$94.03-0.8%2.713 of 5 stars2.71$122.11 29.9%21Analyst ForecastAnalyst Revision1.54%KPTIKaryopharm Therapeutics$0.77-0.4%4.0933 of 5 stars3.00$5.00 547.7%41.54%REPLReplimune Group$11.19-0.4%4.2429 of 5 stars3.17$16.80 50.1%61.51%ZNTLZentalis Pharmaceuticals$3.06-2.2%2.5896 of 5 stars2.44$10.00 226.8%9Analyst Revision1.49%NRIXNurix Therapeutics$22.54-0.4%2.7301 of 5 stars2.93$29.40 30.4%151.48%EXAIExscientia$4.842.2551 of 5 stars2.00$7.00 44.6%4News Coverage1.48%DAWNDay One Biopharmaceuticals$13.37-1.8%2.0003 of 5 stars3.00$35.71 167.1%9Positive News1.47%RXRXRecursion Pharmaceuticals$5.75-4.8%2.0056 of 5 stars2.40$9.25 60.9%5Analyst ForecastOptions Volume1.45%SDGRSchrödinger$19.04-0.7%2.0033 of 5 stars2.82$32.90 72.8%111.45%CRBUCaribou Biosciences$1.94-1.3%2.9415 of 5 stars3.00$11.25 481.4%31.45%SWTXSpringWorks Therapeutics$36.52-2.5%2.0472 of 5 stars3.00$67.00 83.5%7Analyst Forecast1.44%HCMHUTCHMED$17.76-1.1%1.1792 of 5 stars2.67$20.55 15.7%3Analyst DowngradeNews Coverage1.44%JANXJanux Therapeutics$48.35-1.2%3.5987 of 5 stars2.90$66.44 37.4%101.41%ERASErasca$2.60-1.5%2.8149 of 5 stars2.83$6.08 134.0%6Analyst ForecastAnalyst Revision1.41%AURAAura Biosciences$8.76+0.1%3.5197 of 5 stars3.29$23.00 162.6%7Insider TradeAnalyst Revision1.40%ARVNArvinas$23.05+1.6%3.0807 of 5 stars2.93$61.08 165.0%14Analyst ForecastShort Interest ↓News Coverage1.40%MRUSMerus$43.50+1.3%3.0028 of 5 stars3.14$85.45 96.4%14Analyst Forecast1.39%IMCRImmunocore$31.98-1.4%3.012 of 5 stars2.62$69.18 116.3%13Positive News1.38%RPTXRepare Therapeutics$2.85+0.4%2.672 of 5 stars3.33$10.00 250.9%31.36%ACRVAcrivon Therapeutics$6.49-0.2%2.7362 of 5 stars3.00$23.67 264.7%6Analyst Revision1.34%FHTXFoghorn Therapeutics$7.93+0.9%2.655 of 5 stars2.80$16.00 101.8%51.34%KYMRKymera Therapeutics$43.16-2.0%1.4071 of 5 stars2.81$52.13 20.8%16Analyst Forecast1.32%STROSutro Biopharma$2.59-3.0%4.3663 of 5 stars3.00$12.14 368.8%7Analyst ForecastAnalyst Revision1.32%NUVBNuvation Bio$2.57-0.4%2.3313 of 5 stars3.00$6.60 156.8%51.32%RCUSArcus Biosciences$14.36-1.8%2.6831 of 5 stars3.00$34.00 136.8%91.31%CMPXCompass Therapeutics$1.35-1.8%3.4294 of 5 stars2.60$6.75 401.9%51.30%SNDXSyndax Pharmaceuticals$15.27-4.3%4.0171 of 5 stars2.91$37.64 146.5%11Analyst ForecastAnalyst Revision1.28%BCYCBicycle Therapeutics$20.40+0.2%2.8475 of 5 stars2.78$40.13 96.7%9Analyst Revision1.27%CGEMCullinan Therapeutics$12.20-3.0%1.8429 of 5 stars3.00$31.67 159.6%7Analyst Revision1.26%BMEABiomea Fusion$6.15-2.1%3.4326 of 5 stars3.00$30.50 395.9%121.26%ALLOAllogene Therapeutics$2.02-1.5%2.7876 of 5 stars2.75$9.73 381.8%12Short Interest ↓1.26%YMABY-mAbs Therapeutics$10.14-3.8%3.3273 of 5 stars2.89$21.38 110.8%9Analyst Forecast1.25%VORVor Biopharma$0.78-1.5%1.7132 of 5 stars3.00$11.36 1,350.5%71.25%PGENPrecigen$0.84+0.3%3.7724 of 5 stars2.60$7.00 733.7%5Analyst Revision1.25%LYELLyell Immunopharma$1.02-1.5%0.4947 of 5 stars1.50$1.00 -1.5%21.23%IOVAIovance Biotherapeutics$8.10-0.5%4.0475 of 5 stars2.89$22.33 175.7%9Options Volume1.20%GERNGeron$4.04+1.3%3.5118 of 5 stars3.00$7.05 74.5%11 This page (NASDAQ:CNCR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
